Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

2019415 citationsReviewgold Open Access

Authors

Xiaojun Feng · University of Science and Technology of China

Antonio García‐Ríos · Universitat de les Illes Balears

Samineh Jafari · Zanjan University of Medical Sciences

Zahra Memariani · Babol University of Medical Sciences

Devesh Tewari · Lovely Professional University

Giuseppe Annunziata · University of Naples Federico II

Luigi Barrea

Abstract

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.

Topics & Keywords

Berberine and alkaloids research Diet, Metabolism, and Disease Plant-based Medicinal Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Theranostics

Volume 9, Issue 7, pp. 1923-1951

DOI: 10.7150/thno.30787

Field-Weighted Citation Impact: 30.31